Keros Therapeutics, Inc. (KROS)
11.09
-0.14
(-1.25%)
USD |
NASDAQ |
Sep 03, 16:00
11.09
0.00 (0.00%)
After-Hours: 17:02
Keros Therapeutics Research and Development Expense (TTM) : 75.78M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 75.78M |
| March 31, 2026 | 96.95M |
| December 31, 2025 | 129.56M |
| September 30, 2025 | 157.36M |
| June 30, 2025 | 187.07M |
| March 31, 2025 | 184.08M |
| December 31, 2024 | 173.63M |
| September 30, 2024 | 165.49M |
| June 30, 2024 | 150.41M |
| March 31, 2024 | 142.42M |
| December 31, 2023 | 135.26M |
| September 30, 2023 | 129.71M |
| June 30, 2023 | 116.61M |
| March 31, 2023 | 107.36M |
| Date | Value |
|---|---|
| December 31, 2022 | 94.35M |
| September 30, 2022 | 81.23M |
| June 30, 2022 | 75.02M |
| March 31, 2022 | 61.73M |
| December 31, 2021 | 55.14M |
| September 30, 2021 | 45.98M |
| June 30, 2021 | 39.55M |
| March 31, 2021 | 36.83M |
| December 31, 2020 | 33.86M |
| September 30, 2020 | 28.35M |
| June 30, 2020 | 23.81M |
| March 31, 2020 | 21.04M |
| December 31, 2019 | 17.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Incyte Corp. | 2.098B |
| Nurix Therapeutics, Inc. | 332.34M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |